Search results for "Highlights"
Beta-blockers associated with mortality risk in patients with diabetes, study finds
Patients with diabetes who were taking any beta-blocker, a beta-1 selective beta-blocker, or a specific beta-blocker had significantly higher risk for all-cause mortality versus patients with diabetes who were not taking a beta-blocker.
https://diabetes.acponline.org/archives/2018/04/13/2.htm
13 Apr 2018
Impaired glucose tolerance at 1 hour may be more predictive than at 2 hours, study finds
The results highlight the potential benefit of targeting individuals with an elevated one-hour blood glucose level and, if supported by additional evidence, eventually replacing the two-hour test with a one-hour measure, the authors said.
https://diabetes.acponline.org/archives/2017/12/08/2.htm
8 Dec 2017
Benefits of gastric bypass may diminish after 5 years
Patients with type 2 diabetes who had Roux-en-Y gastric bypass surgery maintained significant, although shrinking, improvements in HbA1c compared to those receiving lifestyle and medical management.
https://diabetes.acponline.org/archives/2018/02/09/2.htm
9 Feb 2018
Sociodemographic, clinical factors may influence insulin initiation in type 2 diabetes
The researchers found an inverse association between insulin initiation and age, and black and Hispanic participants were less likely to have insulin initiated compared with white participants.
https://diabetes.acponline.org/archives/2018/02/09/3.htm
9 Feb 2018
Expert panel recommends target ranges for continuous glucose monitoring data
Adults with type 1 and type 2 diabetes should aim to spend more than 70% of each day in the target range of 70 to 180 mg/dL (3.9 to 10.0 mmol/L), which corresponds to an HbA1c level of about 7%, the consensus report said.
https://diabetes.acponline.org/archives/2019/06/14/1.htm
14 Jun 2019
Cardiovascular benefits of adding ezetimibe to statin therapy may be greater in patients with diabetes, study finds
Participants were randomized to receive either ezetimibe or placebo in addition to background simvastatin, and the subgroup of patients with diabetes was compared to those without the disease.
https://diabetes.acponline.org/archives/2018/01/12/2.htm
12 Jan 2018
Individualizing glycemic control could reduce costs, increase quality-adjusted life-years
A cost-effectiveness analysis found that individualized control saved $13,547 per patient compared with uniform intensive control, primarily due to lower medication costs, and increased quality-adjusted life-years by 0.10.
https://diabetes.acponline.org/archives/2018/01/12/3.htm
12 Jan 2018
Insulin pump didn't improve glycemic control compared to training on injections
British patients with type 1 diabetes were enrolled in group training courses that taught flexible intensive insulin treatment and then randomized to an insulin pump or multiple daily injections and followed for two years.
https://diabetes.acponline.org/archives/2017/04/14/3.htm
14 Apr 2017
Cardiovascular event rates similar between once-weekly exenatide and placebo in patients with type 2 diabetes
A limitation of the industry-funded randomized trial was the high rate of early discontinuation: 43.0% of patients on exenatide and 45.2% of those on placebo.
https://diabetes.acponline.org/archives/2017/10/13/1.htm
13 Oct 2017
Risk score may help predict future glycemic control after new diagnosis of diabetes
The most important predictors of the trajectory of glucose control were body mass index and levels of HbA1c and triglycerides, according to the study of registry data from the Netherlands.
https://diabetes.acponline.org/archives/2017/12/08/3.htm
8 Dec 2017